BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20055286)

  • 1. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura.
    Kashif M; Qureshi A; Adil SN; Khurshid M
    J Pak Med Assoc; 2010 Jan; 60(1):64-5. PubMed ID: 20055286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab.
    Ramanathan S; Koutts J; Hertzberg MS
    Am J Hematol; 2005 Feb; 78(2):123-6. PubMed ID: 15682420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
    Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
    Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evan's syndrome complicating multicentric Castleman's disease -- dramatic response to rituximab.
    Quinn JP; Gilligan OM; Horgan M
    Eur J Haematol; 2004 Nov; 73(5):384-5. PubMed ID: 15458520
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient with mixed type Evans syndrome: efficacy of rituximab treatment.
    Park CY; Chung CH
    J Korean Med Sci; 2006 Dec; 21(6):1115-6. PubMed ID: 17179698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in the treatment of refractory autoimmune cytopenias in adults.
    Narat S; Gandla J; Hoffbrand AV; Hughes RG; Mehta AB
    Haematologica; 2005 Sep; 90(9):1273-4. PubMed ID: 16154853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases.
    Mantadakis E; Danilatou V; Stiakaki E; Kalmanti M
    Am J Hematol; 2004 Nov; 77(3):303-10. PubMed ID: 15495242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome.
    Rodella E; Pacquola E; Bianchini E; Ramazzina E; Paolini R
    Blood Coagul Fibrinolysis; 2008 Jun; 19(4):315-8. PubMed ID: 18469554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP).
    Gómez-Almaguer D
    Hematology; 2012 Apr; 17 Suppl 1():S25-7. PubMed ID: 22507772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained remission of CIDP associated with Evans syndrome.
    Knecht H; Baumberger M; Tobòn A; Steck A
    Neurology; 2004 Aug; 63(4):730-2. PubMed ID: 15326255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of a patient with mixed warm and cold antibody mediated Evans syndrome and glucose intolerance.
    Jubinsky PT; Rashid N
    Pediatr Blood Cancer; 2005 Sep; 45(3):347-50. PubMed ID: 15704210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias.
    Gómez-Almaguer D; Solano-Genesta M; Tarín-Arzaga L; Herrera-Garza JL; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Jaime-Pérez JC
    Blood; 2010 Dec; 116(23):4783-5. PubMed ID: 20841509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Favorable response to vinblastine in an idiopathic case of Evans Syndrome].
    Guerrero Becerra MP; Kessler Saiz P; Ortiz Conde MC; Fernández Miranda C
    An Med Interna; 1994 Jul; 11(7):341-4. PubMed ID: 7981362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia.
    Pusiol A; Cesaro S; Nocerino A; Picco G; Zanesco L; Bisogno G
    Eur J Pediatr; 2004 Jun; 163(6):305-7. PubMed ID: 15346911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).
    Scheinberg M; Hamerschlak N; Kutner JM; Ribeiro AA; Ferreira E; Goldenberg J; Kiss MH; Chahade WH
    Clin Exp Rheumatol; 2006; 24(1):65-9. PubMed ID: 16539821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies in the treatment of autoimmune cytopenias.
    Robak T
    Eur J Haematol; 2004 Feb; 72(2):79-88. PubMed ID: 14962245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.
    Heidel F; Lipka DB; von Auer C; Huber C; Scharrer I; Hess G
    Thromb Haemost; 2007 Feb; 97(2):228-33. PubMed ID: 17264951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.